Work

A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC).

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.6023

Authors: Jochen H. Lorch, Naifa Busaidy, Daniel T Ruan, Pasi A. Janne, Sewanti Atul Limaye, Lori J. Wirth, Justine A. Barletta, Guilherme Rabinowits, Levi A. Garraway, Eliezer Mendel Van Allen, Nikhil Wagle, Glenn J. Hanna, Krzysztof Misiukiewicz, Margaret Suda, Tyler C Haddad, Catherine E Devine, Amy Williams, Ghulam Warsi, Marshall R. Posner, Robert I. Haddad

Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Mount Sinai Health System, Mount Sinai Hospital, Novartis (United States)

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597854671

Cites:

Cited by: 25

Related to: 10